21.5
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary chan…
Medical management of cardiomyopathy includes lifestyle modifications such as following a low-salt diet, exercising as tolerated, and avoiding alcohol and tobacco to prevent further cardiac damage.
Treatments often involve ACE inhibitors to reduce afterload, beta-blockers, and aldosterone antagonists to control neurohormonal activity, and diuretics to reduce preload and alleviate symptoms.
Anticoagulants are used if there is a risk of blood clots, and dysrhythmias are treated with appropriate antiarrhythmics.
Severe cases require surgical interventions.
For example, severe hypertrophic cardiomyopathy may require a septal myectomy to remove a portion of the thickened septal wall that obstructs blood flow.
Alternatively, alcohol septal ablation, suitable for those unsuited for open-heart surgery, involves injecting alcohol into a coronary artery to induce controlled infarction and septal thinning.
For dilated cardiomyopathy, mitral valve repair or replacement is recommended to address secondary mitral regurgitation.
Lastly, end-stage heart failure from dilated cardiomyopathy may require ventricular assist device implantation or cardiac transplantation.
View the full transcript and gain access to JoVE Core videos
Q1: What lifestyle modifications help manage cardiomyopathy?
Cardiomyopathy management requires adopting a low-salt diet to reduce fluid retention and prevent further cardiac damage. Patients should follow a personalized exercise and rest plan to maintain fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent exacerbating symptoms and additional heart muscle damage.
Q2: Which medications are commonly used to treat cardiomyopathy?
Common pharmacological treatments include ACE inhibitors like lisinopril and beta-blockers like metoprolol to reduce afterload and control neurohormonal activity. Diuretics like furosemide reduce preload and alleviate symptoms, while aldosterone antagonists help manage heart failure. Anticoagulants prevent blood clots, and antiarrhythmics treat dysrhythmias when present.
Q3: What is septal myectomy and when is it used?
Septal myectomy is an open-heart surgical procedure for severe hypertrophic cardiomyopathy that removes a portion of the thickened septal wall obstructing blood flow. This surgery reduces symptoms and improves exercise capacity. It is the standard surgical intervention when medical management is ineffective for hypertrophic obstructive cardiomyopathy.
Q4: How does alcohol septal ablation differ from septal myectomy?
Alcohol septal ablation is a less invasive alternative to septal myectomy for hypertrophic cardiomyopathy patients unsuited for open-heart surgery. It involves injecting alcohol into a coronary artery to induce controlled infarction and septal thinning. However, it may have higher recurrence rates compared to septal myectomy.
Q5: What surgical options treat dilated cardiomyopathy?
Dilated cardiomyopathy management includes mitral valve repair or replacement to address secondary mitral regurgitation. For end-stage heart failure, left ventricular assist device implantation serves as a bridge to transplantation or long-term therapy. Cardiac transplantation is recommended for patients unresponsive to other treatments.
Q6: How does an implantable cardioverter-defibrillator help cardiomyopathy patients?
An implantable cardioverter-defibrillator (ICD) monitors and corrects life-threatening arrhythmias in cardiomyopathy patients. It significantly reduces the risk of sudden cardiac death and improves overall survival. ICDs are particularly valuable for patients at high risk of dangerous heart rhythm disturbances and provide continuous cardiac protection.
Q7: What role does cardiac resynchronization therapy play in cardiomyopathy treatment?
Cardiac resynchronization therapy (CRT), also called biventricular pacing, benefits patients with dilated cardiomyopathy by coordinating heart contractions. This therapy increases ejection fraction and can reverse some structural changes in the myocardium. It improves cardiac function and reduces heart failure symptoms in appropriately selected patients.